“Glaucoma Pipeline Insight, 2022" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Glaucoma Market.
The Glaucoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
-
The report provides detailed insights about emerging therapies for the treatment of Glaucoma and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glaucoma Treatment.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Glaucoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight’s Report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Latest Clinical and Commercial Developments in the Glaucoma Therapeutics Market
On September 26, 2022, Santen Inc. and UBE Corporation (UBE) announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension.
Learn How the Ongoing Clinical & Commercial Activities will Affect the Glaucoma Therapeutic Segment:
https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
Glaucoma Therapeutics Landscape
In general, glaucoma cannot be cured, but it can be controlled. Eye drops, pills, laser procedures, and surgical operations are used to prevent or slow further damage from occurring. With any type of glaucoma, regular eye examinations are very important to detect progression and prevent vision loss.
There are approx. 70+ key companies which are developing therapies for Glaucoma. Currently, Nicox has its Glaucoma drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Glaucoma Therapeutics Market include:
Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, AbbVie, JeniVision, Inc., Ocular Therapeutix, Annexon, Inc., Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, and several others.
Glaucoma Drugs Covered in the report include:
• QLS-101: Qlaris Bio, Inc.
• NCX 470: Nicox
And many more
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:
https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Glaucoma Current Treatment Patterns
4. Glaucoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glaucoma Late Stage Products (Phase-III)
7. Glaucoma Mid-Stage Products (Phase-II)
8. Glaucoma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glaucoma Discontinued Products
13. Glaucoma Product Profiles
14. Key Companies in the Glaucoma Market
15. Key Products in the Glaucoma Therapeutics Segment
16. Dormant and Discontinued Products
17. Glaucoma Unmet Needs
18. Glaucoma Future Perspectives
19. Glaucoma Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Hyperglycemia Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Hyperglycemia Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
